Moderna stock tumbled 10.5 percent in pre-market trading early Wednesday morning, after the Food and Drug Administration rejected the drug giant’s application for an experimental flu vaccine using mRNA technology. […]

The post Overnight: Moderna Stock Price Took a Steep Drop After FDA Rejected MRNA-Based Flu Shot Late Tuesday appeared first on The Western Journal.